Pyruvate Kinase Deficiency (PKD) is an autosomal recessive enzyme defect of the glycolytic pathway that causes congenital, non-spherocytic hemolytic anemia.  The diagnosis and management of patients with PKD can be challenging due to difficulties in the diagnostic evaluation and the heterogeneity of clinical manifestations, ranging from fetal hydrops and symptomatic anemia requiring lifelong transfusions to fully compensated hemolysis.  Current treatment approaches are supportive and include transfusions, splenectomy, and chelation.  Complications, including iron overload, bilirubin gallstones, extramedullary hematopoiesis, pulmonary hypertension, and thrombosis, are related to both the chronic hemolytic anemia and its current management, and can occur at any age.  Disease-modifying therapies in clinical development may decrease symptoms and findings associated with chronic hemolysis and avoid the complications associated with current treatment approaches.  As these disease-directed therapies are approved for clinical use, clinicians will need to define the types of symptoms and findings that determine the optimal patients and timing for initiating these therapies.  In this article, we highlight disease manifestations, monitoring approaches, strategies for managing complications, and novel therapies in development.

This content is only available as a PDF.

Article PDF first page preview

Article PDF first page preview
You do not currently have access to this content.